The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Medically reviewed by Suzanne Fisher, RD Hypoglycemia (low blood sugar) treatments will depend on the severity of symptoms ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student ...

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Glucagon is a recognised therapy for the disorder ... 2019 as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication.

May give additional doses (using a new nasal spray) every 2–3mins in alternate nostrils if unresponsive or relapses into respiratory depression.